Show simple item record

dc.contributor.authorHowell, Sacha J
dc.contributor.authorSearle, C
dc.contributor.authorGoode, Valerie
dc.contributor.authorGardener, T
dc.contributor.authorLinton, Kim M
dc.contributor.authorCowan, Richard A
dc.contributor.authorHarris, Maggie A
dc.contributor.authorHopwood, Penelope
dc.contributor.authorSwindell, Ric
dc.contributor.authorNorman, Alison
dc.contributor.authorKennedy, Jennifer
dc.contributor.authorHowell, Anthony
dc.contributor.authorWardley, Andrew M
dc.contributor.authorRadford, John A
dc.date.accessioned2009-11-05T11:27:39Z
dc.date.available2009-11-05T11:27:39Z
dc.date.issued2009-08-18
dc.identifier.citationThe UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. 2009, 101 (4):582-8 Br. J. Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid19672261
dc.identifier.doi10.1038/sj.bjc.6605215
dc.identifier.urihttp://hdl.handle.net/10541/85383
dc.description.abstractBACKGROUND: Supradiaphragmatic radiotherapy (SRT) to treat Hodgkin's lymphoma (HL) at a young age increases the risk of breast cancer (BC). A national notification risk assessment and screening programme (NRASP) for women who were treated with SRT before the age of 36 years was instituted in the United Kingdom in 2003. In this study, we report the implementation and screening results from the largest English Cancer Network. METHODS: A total of 417 eligible women were identified through cancer registry/hospital databases and from follow-up (FU) clinics. Screening results were collated retrospectively, and registry searches were used to capture BC cases. RESULTS: Of the 417 women invited for clinical review, 243 (58%) attended. Of these 417 women, 23 (5.5%) have been diagnosed with BC, a standardised incidence ratio of 2.9 compared with the age-matched general population. Of five invasive BCs diagnosed within the NRASP, none involved axillary lymph nodes compared with 7 of 13 (54%) diagnosed outside the programme (P<0.10). The mean latency for BC cases was 19.5+/-8.35 years and the mean FU duration for those unaffected by BC was 14.6+/-9.11 years (P<0.01), suggesting that those unaffected by BC remain at high risk. Recall and negative biopsy rates were acceptable (10.5 and 0.8%, respectively). CONCLUSIONS: The NRASP appears to detect BC at an early stage with acceptable biopsy rates, although numbers are small. Determination of NRASP results on a national basis is required for the accurate evaluation of screening efficacy in women previously treated with SRT.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectRadiation-Induced Canceren
dc.subjectSecond Primary Canceren
dc.subject.meshAdult
dc.subject.meshBreast Neoplasms
dc.subject.meshFemale
dc.subject.meshGreat Britain
dc.subject.meshHodgkin Disease
dc.subject.meshHumans
dc.subject.meshMammography
dc.subject.meshMass Screening
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms, Radiation-Induced
dc.subject.meshNeoplasms, Second Primary
dc.subject.meshRadiotherapy
dc.subject.meshRegistries
dc.subject.meshRetrospective Studies
dc.subject.meshRisk Factors
dc.subject.meshSurvivors
dc.titleThe UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK. Showell@picr.man.ac.uken
dc.identifier.journalBritish Journal of Canceren
html.description.abstractBACKGROUND: Supradiaphragmatic radiotherapy (SRT) to treat Hodgkin's lymphoma (HL) at a young age increases the risk of breast cancer (BC). A national notification risk assessment and screening programme (NRASP) for women who were treated with SRT before the age of 36 years was instituted in the United Kingdom in 2003. In this study, we report the implementation and screening results from the largest English Cancer Network. METHODS: A total of 417 eligible women were identified through cancer registry/hospital databases and from follow-up (FU) clinics. Screening results were collated retrospectively, and registry searches were used to capture BC cases. RESULTS: Of the 417 women invited for clinical review, 243 (58%) attended. Of these 417 women, 23 (5.5%) have been diagnosed with BC, a standardised incidence ratio of 2.9 compared with the age-matched general population. Of five invasive BCs diagnosed within the NRASP, none involved axillary lymph nodes compared with 7 of 13 (54%) diagnosed outside the programme (P<0.10). The mean latency for BC cases was 19.5+/-8.35 years and the mean FU duration for those unaffected by BC was 14.6+/-9.11 years (P<0.01), suggesting that those unaffected by BC remain at high risk. Recall and negative biopsy rates were acceptable (10.5 and 0.8%, respectively). CONCLUSIONS: The NRASP appears to detect BC at an early stage with acceptable biopsy rates, although numbers are small. Determination of NRASP results on a national basis is required for the accurate evaluation of screening efficacy in women previously treated with SRT.


This item appears in the following Collection(s)

Show simple item record